BioTuesdays

Tag - Stifel

Alphatec Spine Logo
Markets

Stifel starts Alphatec at buy; PT $13

Stifel initiated coverage of Alphatec Holdings (NASDAQ:ATEC) with a “buy” rating and $13 price target. The stock closed at $9.88 on Oct. 19. Alphatec engages in design, development, and marketing of spinal fusion...

October 19, 2020
SeaSpine Holdings
Markets

Stifel starts SeaSpine at buy; PT $22

Stifel launched coverage of SeaSpine Holdings (NASDAQ:SPNE) with a “buy” rating and price target of $22. The stock closed at $14.97 on Oct. 19. “After several years of uneven performance post the 2015 spin-out from...

October 19, 2020
Nurix Logo
Markets

Stifel starts Nurix Therapeutics at buy; PT $34

Stifel initiated coverage of Nurix Therapeutics (NASDAQ:NRIX) with a “buy” rating and $34 price target. The stock closed at $27 on Aug. 17. Nurix is a soon-to-be-clinical-stage company focused on the discovery...

August 18, 2020
CymaBay
Markets

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

May 12, 2020
Radius Health Logo
Markets

Stifel starts Radius Health at hold; PT $20

Stifel initiated coverage of Radius Health (NASDAQ:RDUS) with a “hold” rating and $20 target price. The stock closed at $17.18, up $1.43, on April 23. Analyst Annabel Samimy writes that Radius established a solid...

April 24, 2020
Cue Biopharma Logo
Markets

Stifel starts Cue Biopharma at buy; PT $21

Stifel initiated coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $21 price target. The stock closed at $16.60, up $1.53, on April 8. “We believe the Immuno-STAT platform from which the company’ wholly...

April 9, 2020
Molecular Templates
Markets

Stifel starts Molecular Templates at buy; PT $19

Stifel initiated coverage of Molecular Templates (NASDAQ:MTEM) with a “buy” rating and $19 price target. The stock closed at $13.29 on March 24. “We believe the engineered toxin body technology from which Molecular’s...

March 25, 2020
AdaptHealth
Markets

Stifel starts AdaptHealth at buy; PT $17

Stifel initiated coverage of AdaptHealth (NASDAQ:AHCO) with a “buy” rating and $17 price target. The stock closed at a 52-week high of $13 on Jan. 30. “AdaptHealth is a unique asset poised to capitalize on an ongoing...

January 31, 2020
CymaBay
Markets

Stifel cuts CymaBay to hold; PT to $4 from $14

Stifel downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “hold” from “buy” and slashed its price target to $4 from $14 after the company halted development of its sole value driver, seladelpar. The stock closed at $5.55...

November 25, 2019

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.